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Abstract
Background: Neonatal growth is a complex process involving genetic and environmental factors. Polymorphisms
in the hemochromatosis (HFE) iron regulatory genes have been shown to modify transport and toxicity of lead
which is known to affect birth weight.
Methods: We investigated the role of HFE C282Y, HFE H63 D, and transferrin (TF) P570 S gene variants in modifying
the association of lead and infant birthweight in a cohort of Mexican mother-infant pairs. Subjects were initially
recruited between 1994-1995 from three maternity hospitals in Mexico City and 411 infants/565 mothers had
archived blood available for genotyping. Multiple linear regression models, stratified by either maternal/infant HFE
or TF genotype and then combined with interaction terms, were constructed examining the association of lead
and birthweight after controlling for covariates.
Results: 3.1%, 16.8% and 17.5% of infants (N = 390) and 1.9%, 14.5% and 18.9% of mothers (N = 533) carried the
HFE C282Y, HFE H63D, and TF P570 S variants, respectively. The presence of infant HFE H63 D variants predicted
110.3 g (95% CI -216.1, -4.6) decreases in birthweight while maternal HFE H63 D variants predicted reductions of
52.0 g (95% CI -147.3 to 43.2). Interaction models suggest that both maternal and infant HFE H63 D genotype may
modify tibia lead’s effect on infant birthweight in opposing ways. In our interaction models, maternal HFE H63 D
variant carriers had a negative association between tibia lead and birthweight.
Conclusions: These results suggest that the HFE H63 D genotype modifies lead’s effects on infant birthweight in a
complex fashion that may reflect maternal-fetal interactions with respect to the metabolism and transport of
metals.
Background
Decreased birthweight has been established as a predic-
tor of infant mortality, morbidity, developmental out-
comes such as cognitive performance, and chronic
disease into adulthood [1]. Both environmental and
genetic factors contribute to the weight of an infant at
birth. Environmental factors that have been associated
with birth weight include, but are not limited to: mater-
nal nutritional status [2], maternal infections [3], parity,
and exposure to toxicants, such as lead [4]. Two recent
population studies have estimated that approximately
50% of the variation in birthweight is due to heritable
maternal/infant factors [5,6]. Genetic components which
metabolize, respond to, or regulate environmental fac-
tors, such as lead exposure, would be strong candidates
for studying gene-environment interactions.
Environmental exposure to lead [1] and iron defi-
ciency [7,8] continue to contribute significantly to
worldwide infant mortality and neurodevelopmental
toxicity. Decreases in birth weight have been indepen-
dently associated with increased lead exposure [4,9] and
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extremes in iron status [10,11]. These effects may be
compounded when women are both iron deficient and
exposed to lead during pregnancy, because lead absorp-
tion is upregulated during iron deficiency [12,13].
Iron uptake across cell membranes is complex and
regulated by multiple proteins including transport pro-
teins such as transferrin (TF), divalent metal transpor-
ter-1 (DMT-1), and ferroportin, their receptors, as well
as regulatory proteins such as HFE and hepcidin [14].
The HFE gene is of particular interest in public health
research because it contains two highly prevalent func-
tional variants, C282Y and H63 D [15]. Several studies
have indicated that HFE variants alone can be important
modifiers of lead susceptibility to health outcomes
[16,17] and these effects appear to be age dependent.
For example, Wright et. al. showed that older adult car-
riers of either HFE variant genotype (H63 D or C282Y),
had lower blood, patella bone, and tibia bone lead stores
when compared to wildtype individuals [18]. Conversely,
it was demonstrated that iron metabolism gene variants
in both HFE and TF were associated with increased
blood lead levels in Mexican children [19].
The aim of this study was to explore both the main
gene and the interactive effects between variants in the
iron regulatory protein gene HFE (C282Y and H63D),
the iron transport protein gene TF (P570S), and biomar-
kers of neonatal lead exposure on infant birth weight.
We hypothesized that: 1) maternal/infant HFE and TF
variant genotypes would both independently and jointly
modify infant birthweight; and, 2) HFE variant and TF
variants could be protective against the negative effects
of lead exposure on birth weight since they could foster
adequate iron stores that would compete for common
transport receptors.
Methods
Sample population
Maternal/infant pairs were recruited between 1994 and
1995 from three hospitals in Mexico City which serve
low-to-moderate income populations as part of a clinical
trial to assess calcium supplementation effects on mater-
nal bone lead mobilization during lactation using meth-
ods previously described [4,20]. Of the original cohort of
617 mother-infant pairs enrolled, there were 411 infants
and 565 mothers who had archived blood available for
genotyping for this analysis.
The study protocol was approved by the Ethics Com-
mittee of the National Institute of Public Health of
Mexico, the participating hospitals, the Brigham and
Women’s Hospital, and the Harvard School of Public
Health. All participating mothers signed a written con-
sent form, received a detailed explanation of the study
intent and research procedures, as well as counseling on
how to reduce environmental lead exposure.
Anthropometric measurements
Neonates were weighed at delivery by experienced
obstetric nurses using calibrated beam scales (Oken,
Model TD16, Naucalpan, Mexico) read to the nearest
10 grams. Maternal anthropometric measures were col-
lected by our trained project personnel and standardized
according to the technique described by Habicht [21].
These standardization exercises were performed until
the project staff reached imprecision errors equal to or
below those reported by Lohman and coworkers [22].
Accepted technical errors were 0.3 cm for arm circum-
ference and 0.22 cm for height.
Blood lead measurements
Umbilical cord blood samples were collected in trace
metal-free tubes at delivery. Blood samples were ana-
lyzed using an atomic absorption spectrometry instru-
ment (Perkin-Elmer 3000, Chelmsford, MA, USA) at the
metals laboratory of the American British Cowdray Hos-
pital in Mexico City. External blinded quality-control
samples were provided throughout the study period by
the Maternal and Child Health Bureau and the Wiscon-
sin State Laboratory of Hygiene Cooperative Blood Lead
Proficiency Testing Program. Our laboratory maintained
acceptable precision and accuracy over the study period
[correlation = 0.98; mean difference = 0.71 μg/dL; SD =
0.68].
Maternal bone lead measurements
Maternal bone lead was measured non-invasively using a
spot-source 109Cd K-XRF instrument constructed at
Harvard University and installed in a research facility in
the American British Cowdray Medical Center. For this
study, 30-minute in vivo maternal bone lead measure-
ments were taken within one month of delivery at two
bone sites, the mid-tibial shaft (cortical bone) and the
patella (trabecular bone). The physical principles, techni-
cal specifications, and validation of this and other simi-
lar K-XRF instruments have been described in detail
elsewhere [23].
Genotyping methods
DNA extraction and genotyping were performed in The
Harvard-Partners Center for Genetics and Genomics.
High-molecular-weight DNA was extracted with com-
mercially available PureGene Kits (Gentra Systems, Min-
neapolis, MN) from the white blood cells of archived
maternal and umbilical cord blood samples. Genotyping
for the hemochromotosis HFE C282Y (RS1800562), HFE
H63 D (RS1799945) and transferrin TF P570 S
(RS1049296) variants was performed using Sequenom
MALDI-TOF (Matrix-assisted laser desorption ioniza-
tion - time of flight) mass spectrometry according to the
methods that have been described earlier [19].
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Statistical analyses
Descriptive statistics and identification of outliers, using
the generalized extreme studentized deviation method
[24] were performed. Distribution of HFE and TF alleles
and genotypes were examined and frequencies were
tested using a chi-square statistic to compare observed
and expected counts according to principles of Hardy-
Weinberg equilibrium. Due to the low prevalence of
HFE C282Y variants in this population, this variant was
excluded from further analyses. Individuals homozygous
for HFE H63 D (N = 4 infants, N = 3 mother) and
those who were compound heterozygotes with HFE
C282Y (N = 2 infants, N = 1 mother) were removed
from analysis due to population studies that demon-
strate those individuals may have significantly increased
iron levels when compared to carrier individuals (Jack-
son et al. 2001). Remaining individuals with heterozy-
gous variant genotypes were compared separately to
participants with wild type genotypes for each of the
two remaining variants (HFE H63 D and TF 570S).
Demographic characteristics and lead levels by geno-
type were examined and mean differences were tested by
chi-square or Student’s t-test (2-tailed) for continuous
and categorical variables as appropriate. Potential non-
linearity between continuous predictor variables and
birth weight was explored by plotting results from gener-
alized additive models. Resulting non-linear associations
were controlled for as covariates, in multiple linear
regression models which included either the maternal
HFE H63 D or TF P570 S genotype, by adding a squared
term for maternal age and dummy variables for maternal
education (years of education: <8, 8 -11, 11>). Multiple
linear regression was then used to model the relationship
between birthweight, maternal and infant HFE H63 D
and TF P570 S genotypes, and biomarkers of lead expo-
sure, after controlling for potential confounding variables.
The potential confounding variables considered in our
models were based on biologic plausibility (maternal age
at delivery (years), maternal education (years), cigarette
smoking during pregnancy (yes/no), gestational age
(weeks), infant gender (female gender as reference
group), and parity (total number of live births), or those
significantly associated with birthweight (p < 0.1) in
bivariate analysis (maternal postpartum arm circumfer-
ence (cm)( (which served as proxy for gestational weight
gain), maternal hemoglobin at 1 month post-partum, and
marital status (single/partnered.) To examine the poten-
tial modifying effect of the variants, we initially ran sepa-
rate multiple linear regression models stratified by
maternal or infant genotype. On the basis of the differ-
ences in effect estimates of tibia bone lead on birthweight
in stratified models, we fitted multiple linear regression
models that included an interaction term between the
genotype and tibia bone lead.
Regression diagnostics were performed on all models
to evaluate multicollinearity and violations of the linear
regression model assumptions. Data were analyzed using
SAS 9.1, SAS Institute Inc. Cary, NC, 2002-2003 and R
2.9.1, (The R Foundation for Statistical Computing, Bos-
ton, MA 2007.
Results
Our final study population included 533 genotyped
mothers of whom 1.9%, 14.5%, and 18.9% carried the
HFE C282Y, HFE H63D, and TF P570 S variant, respec-
tively. Additionally, 390 genotyped children were
included and 3.1%, 16.8%, and 17.5% carried the HFE
C282Y, HFE H63D, and TF P570 S variants, respectively
(Table 1). All genotype distributions were found to con-
form to Hardy-Weinberg equilibrium expectations. After
taking into consideration both maternal and infant HFE
H63 D genotype status, 20 (5.4%) mothers carried the
HFE H63 D variant while their infants were wildtype, 32
(8.6%) mothers were wildtype while their infants carried
the HFE H63 D variant, and 40 (10.8%) were both het-
erozygous for HFE H63D.
Table 2 shows the distribution of lead biomarkers and
covariates stratified by maternal and infant HFE H63 D
and TF P570 S genotypes. Mean infant birth weight was
slightly lower in infant HFE H63 D carriers when com-
pared to infant HFE H63 wild-type individuals. There
were no significant differences between maternal HFE
H63 D variants and maternal wild-type individuals.
Maternal hemoglobin at one month post partum were
significantly increased in maternal genotype TF P570 S
variants when compared to maternal TF P570 wild-type
individuals respectively.
There were 59 (12.6%) infants with cord blood lead
levels exceeding 10 μg/dL. Additionally, 147 (26.0%)
mothers were anemic based on criteria for evaluating
lactating women living at an altitude of 7,000 - 7,999
feet above sea level [25]. Cord blood lead failed to pre-
dict a significant association with birthweight after con-
trolling for covariates of interest (Table 3). A one-unit
change in tibia bone lead predicted a decrease of 4.4 g
(95%CI: -7.9, -0.9) in birthweight after controlling for
covariates of interest. Using the lowest quartile of tibia
lead as the reference group, the highest quartile of tibia
lead predicted a 95.4 gram (95%CI: -189.9, -0.8) gram
decrease in birth weight and the trend across quartiles
had a p-value of 0.06.
Results from generalized additive models indicated
that gestational age had a slight non-linear association
with birthweight. Additionally, in models with the
maternal HFE H63 D or TF P570 S variants, maternal
age and maternal education had significant non-linear
relationships. To control for this effect, any models
including the maternal HFE H63 D or TF P570 S
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included additional covariates: maternal age squared and
tertiles of maternal education.
Table 4 lists the main gene effects for maternal/infant
HFE H63 D and TF P570 S upon infant birthweight.
After controlling for tibia bone lead and potential con-
founding variables of birth weight in multivariate analysis
(maternal age at delivery in years, maternal years of edu-
cation, maternal arm circumference, cigarette smoking
during pregnancy (yes/no), gestational age in weeks,
infant sex, maternal hemoglobin at 1 month post-partum,
and parity), the presence of the infant and maternal
variant HFE H63 D gene predicted a 129.5 g (95% CI:
-236.4, -22.6) and 53.7 g (95% CI: -148.9, 41.5) decrease
in birthweight respectively. The presence of both a
maternal and infant HFE H63 D variant genotype pre-
dicted a decrease of 176.9 g (95% CI: -318.6 to -35.3) in
birthweight. Main effects of maternal and infant transfer-
rin variant genotypes on birthweight were non-signifi-
cant. When both compound heterozygotes and HFE H63
D homozygote individuals were included as “carriers (i.e.
recoded as HFE = 1 versus HFE = 0 for wildtype) pre-
sence of the infant and maternal variant HFE H63 D gene
Table 1 Maternal and Infant HFE and TF Genotype Frequencies
Mother Infant
Genotype Number % Genotype Number %
HFE (C282Y) HFE (C282Y)
C282 Wildtype (CC) 523 98.1 C282 Wildtype (CC) 378 96.9
C282Y Heterozygous (CY) 10 1.9 C282Y Heterozygous (CY) 10 3.1
C282Y Homozygous (YY) 0 0 C282Y Homozygous (YY) 0 0
Hardy-Weinberg equilibrium: c2 = 0.05, p = 0.83 Hardy-Weinberg equilibrium: c2 = 0.10, p = 0.76
HFE (H63D) HFE (H63D)
H63 Wildtype (HH) 452 85.0 H63 Wildtype (HH) 319 82.2
H63 D Heterozygous (HD) 77 14.5 H63 D Heterozygous (HD) 65 16.8
H63 D Homozygous (DD) 3 0.5 H63 D Homozygous (DD) 4 1.0
Hardy-Weinberg equilibrium: c2 = 0.02, p = 0.87 Hardy-Weinberg equilibrium: c2 = 0.11, p = 0.74
TF (P570S) TF (P570S)
P570 Wildtype (PP) 429 80.9 P570 Wildtype (PP) 319 82.0
P570 S Heterozygous (PS) 100 18.9 P570 S Heterozygous (PS) 68 17.5
P570 S Homozygous (SS) 1 0.2 P570 S Homozygous (SS) 2 0.5
Hardy-Weinberg equilibrium: c2 = 3.81, p = 0.05 Hardy-Weinberg equilibrium: c2 = 0.65, p = 0.42
Table 2 Study population characteristics by Maternal HFE H63 D and TF P570 S genotype
H63
Wildtype
H63 D
Variant
TF
Wildtype
TF
Variant
Age (years) 24.5 (5.0) 23.9 (5.2) 24.4 (5.0) 24.4 (5.2)
Education (years) 9.3 (3.0) 9.3 (2.9) 9.4 (3.0) 9.3 (3.1)
Arm circumference 26.4 (2.7) 26.2 (2.5) 26.3 (2.7) 26.6 (2.7)
Smoking during pregnancy 4.7% 2.7% 4.7% 3.0%
Primiparity 43.6% 49.3% 44.3% 41.4%
Hemoglobin 1 month (g/dL) 13.6 (1.5) 13.6 (1.6) 13.5 (1.5) 13.8 (1.4)**
Marital Status (% Married) 65.5% 61.3% 64.5% 64.7%
Tibia Bone Lead (ug/g) 10.1 (9.7) 8.7 (9.3) 10.1 (9.8) 9.4 (9.0)
Gestational Age (days) 39.3 (1.4) 39.1 (1.4) 39.2 (1.4) 39.4 (1.3)
Birthweight (grams) 3162.2 (418.1) 3091.7 (415.8) 3156.6 (420.4) 3134.5 (404.9)
Sex (% Male) 54.9% 50.7% 54.7% 54.6%
Cord Blood Lead (μg/dL) 6.6 (3.5) 6.3 (4.2) 6.5 (3.5) 6.9 (1.3)
*P(< 0.1), **P(< 0.05)
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predicted a 89.6 g (95% CI: -190.9, 11.9) and 49.4 g (95%
CI: -142.1, 43.2) decrease in birthweight respectively.
We next examined the potential effect modification by
HFE and TF genotype on the adverse relationship
between maternal bone lead levels and birthweight listed
in table 5. We found that the maternal HFE H63 D gen-
otype may modify the relationship between tibia lead
and birthweight by enhancing the negative effect in
maternal HFE H63 D variants. The coefficient for the
interaction term between tibia lead and maternal HFE
H63 D genotype was -10.3 (p = 0.05). This relationship
persisted when we modeled infant-maternal genotype
interactions as dummy variables; maternal HFE H63 D
variants who gave birth to infant HFE H63 wildtypes
had an enhanced negative effect of tibia lead on birth-
weight with an interaction term of -28.7 (P = 0.003).
Effect modification by infant HFE H63 D and TF P570 S
status on the tibia lead-birthweight relationship were
not significant, but suggested a positive direction for
effect modification. There were no significant interac-
tions between maternal blood at delivery or cord blood
and genotype status (data not shown.)
Discussion
Our results demonstrate that the infant HFE H63 D var-
iant genotype predicts a decrease in birth weight. In
Table 3 Adjusted parameter estimates for birthweight by
biological markers of lead exposure in separate linear
regression modelsa
Variable N b P-value 95% CI
Cord Blood Lead (μg/dL) 464 -31.1 0.41 -105.4,
43.3
Maternal Blood at Delivery
(μg/dL)
526 9.3 0.80 -64.2, 82.9
Tibia Lead Continuous (μg/g) 538 -4.4 0.01 -7.9, -0.9
Tibia Lead Quartiles
Q1 (< 1 - 4.1) 137 Reference
Q2 (4.1 - 9.2) 137 17.2 0.72 -75.6,
110.1
Q3 (9.2 - 15.4) 137 -19.1 0.69 -112.1,
73.9
Q4 (15.4 - 43.2) 137 -95.4 0.05 -189.9,
-0.8
P-Trend 0.06
aAll models are adjusted for maternal age, years of maternal education, infant
gender, maternal arm circumference, gestational age, smoking status during
pregnancy, marital status, maternal hemoglobin one month post-partum, and
parity
Number - N, Coefficient - b, Confidence Interval - CI.
Table 4 Adjusted parameter estimates for the association of HFE H63 D and TF P570 S genotype status and
birthweight, in separate linear regression modelsa
Model Variable N b 95% CI
1 Infant HFE H63 D Genotype 367 -129.5** -236.4, -22.6
2 Infant TF P570 S Genotype 371 34.9 -68.3,138.2
3 Maternal HFE H63 D Genotypeb 502 -53.7 -148.9, 41.5
4 Maternal TF P570 S Genotypeb 503 -62.6 -148.5, 23.4
5 H63Inf. Wildtype/H63Mat.Wildtype Referent (N = 260)
H63Inf. Wildtype/H63DMat.Variant 16 94.7 -99.0, 288.4
H63DInf. Variant/H63Mat.Wildtype 24 -77.4 -240.9, 86.1
H63DInf. Variant/H63DMat.Variant 32 -176.9** -318.6, -35.3
6 TFInf. Wildtype/TFMat.Wildtype Referent (N = 252)
TFInf. Wildtype/TFMat.Variant 31 -63.2 -207.2, 80.8
TFInf. Variant/TFMat.Wildtype 27 66.9 -88.6, 222.3
TFInf. Variant/TFMat.Variant 27 -36.4 -190.1,117.2
aAll models are adjusted for maternal age, years of maternal education, infant gender, maternal arm circumference, gestational age, smoking status during
pregnancy, marital status, maternal tibia lead, maternal hemoglobin at 1 month post-partum, and parity.
bAll models additionally adjusted for maternal age2, and dummy variables for maternal education (years of education: <8, 8 -11, 11>) to account for the non-
linear nature of these covariates.
** P-value < 0.05, * P-value < 0.1
Infant - Inf., Maternal - Mat. Number - N, Coefficient - Coef., Confidence Interval - CI
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multiple linear regression models, the infant HFE H63 D
allele predicted a decrease of 129.5 grams (95%CI:
-236.4, -22.6) in infant birth weight after controlling for
covariates of interest, including tibia lead levels. The
combined effects of both the maternal and infant HFE
H63 D variant genotype predicted a greater decrease in
birthweight of 176.9 grams (95%CI: -318.6, -35.3). This
would suggest that maternal-fetal genotypes are interac-
tive for this gene, an interesting and unique finding.
Finally, the maternal HFE H63 D variant allele predicted
enhanced negative effects of maternal bone lead on
birthweight. To our knowledge this study is the first to
observe effect modification of the association between
lead exposure and birth weight by HFE genotype status.
Because iron is a critical nutrient, has been related to
lead absorption, and has been linked to birthweight pre-
viously, studies of iron metabolism gene variants are
logical candidates to either directly impact birthweight
or modify the effect of lead on birthweight. Our study
focused on two well known functional variants within
iron metabolism genes. The independent effects of HFE
on birth weight have only been studied in one other
study [26]. In Maier and colleagues’ study, very low
birth weight infants (< 1500 g) were assessed for HFE
C282Y genotype and transferrin saturation. Although
the study observed no association between HFE C282Y
genotype, transferrin saturation and very low birth
weight, it should be noted that only six infants were het-
erozygous for the HFE C282Y mutation so the study was
very underpowered to test this hypothesis. Our study
differs from Maier et. al. in that we had no very low
birth weight infants and instead chose to look at the
continuous measure of birth weight.
A mechanistic role for the interaction between HFE,
lead, and birth weight may lie both within the role of
iron status as a modifier of lead absorption and the role
of iron as a toxicant. Previous studies on lead uptake
during iron deficient conditions have demonstrated that
both lead and iron compete for binding to the DMT-1
transporter [27,28]. On the apical plasma membrane of
syncytiotrophoblastic cells in human placenta, HFE
associates with the transferrin receptor and on the basal
side with ferroprotin and DMT-1, suggesting a potential
role in iron transport across the placenta [29-33]. Disre-
gulation in HFE has been shown to increase DMT-1
mediated intestinal uptake of iron, but studies are lack-
ing for these effects upon lead absorption or in placental
transfer [34-37]. In human epidemiological studies, pre-
sence of the HFE H63 D variant resulted in higher child
blood lead levels [19]. Taken together these previous
Table 5 Adjusted regression coefficients for effect modification of HFE or TF genotype upon tibia lead’s adverse
association with birthweighta
Model Genotype Genotype Variant Tibia
Lead
Interaction
Term
1 Infant HFE H63D -127.5** -6.5** 4.5
2 Infant TF P570S 34.9 -5.8** 0.9
3 Maternal HFE H63 D b -62.7 -3.0 -10.3**
4 Maternal TF P570 S b -60.8 -5.7** 6.8
5 Maternal/Infant HFE H63 D Interactions
H63Inf. Wildtype/H63Mat.Wildtype Referent
H63Inf. Wildtype/H63DMat.Variant 143.0 -4.5* -28.7**
H63DInf. Variant/H63Mat.Wildtype -64.2 6.2
H63DInf. Variant/H63DMat.Variant -177.2** -6.0
6 Maternal/Infant TF P570 S Interactions
TFInf. Wildtype/TFMat.Wildtype Referent
TFInf. Wildtype/TFMat.Variant -51.7 -7.2** 10.3
TFInf. Variant/TFMat.Wildtype 66.7 -4.5
TFInf. Variant/TFMat.Variant -40.5 9.3
aAll models are adjusted for maternal age, years of maternal education, infant gender, maternal arm circumference, gestational age, smoking status during
pregnancy, maternal hemoglobin one month post-partum, and parity.
bAll models additionally adjusted for maternal age2, and dummy variables for maternal education (years of education: <8, 8 -11, 11>) to account for the non-
linear nature of these covariates.
* P-value < 0.1, ** P-value < 0.05
Infant - Inf., Maternal - Mat.
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studies could explain, in part, the increased risk of low
birthweight for infants with the H63 D allele though
this effect may not be limited to changes in lead absorp-
tion/metabolism since excess iron itself is potentially
toxic.
Previous research has also shown a U-shaped relation
where both maternal iron deficiency and iron excess can
increase risk of preterm delivery and decrease infant
birthweight [38-42]. Researchers have shown that in
response to low iron and anemic conditions in early and
late pregnancy changes in placental morphology can
occur. These changes manifest as larger weight placen-
tas with observed increases in villous volume and sur-
face areas of the capillaries involved in gas exchange,
which thought to be a response to hypoxic conditions
that would limit growth [43-46]. Alternatively, the pro-
duction of reactive oxygen species resulting from reac-
tive iron species, like unbound iron, is thought to be the
major mechanistic contributor to the damage done by
iron excess [38,47,48]. Exposure to lead has also been
shown to disrupt the balance between reactive oxygen
species and antioxidant cellular defenses [49,50]. The
H63 D allele may act both by increasing iron to subcli-
nical toxic levels and by increasing lead. We hypothesize
that a disruption in the delicate balance of pro-oxidant/
antioxidant molecules either through excess/deficiency
of iron and exposure to lead could impair birth weight.
We speculate that these effects could be enhanced when
both the mother and infant carry the variant allele
potentially due to a similar mechanistic pathway. The
enhancement of lead’s negative effects by maternal HFE
H63 D variant status indicated by our results may also
be mediated through such a mechanism. Further
research is needed in order to gain a greater under-
standing of how biologically useful metals interact with
toxic metals and how these interactions may modify
health effects.
Many past gene-environment epidemiological studies
which focus on reproductive outcomes tend only to report
either maternal or fetal genotype results while neglecting
the combined maternal-fetal genetic susceptibility. In our
study we found that while infants who carry the H63 D
variant are adversely associated with birthweight, it was
the infant H63 D carriers born to mothers which are also
H63 D carriers that had the greatest adverse association
with birthweight. Several other recent studies have
observed similar relationships where maternal/infant var-
iant-variant carriers show the greatest extremes in risk for
adverse birth outcome [51-54].
As with any study, there are limitations. In our study we
did not have a direct measure of maternal iron status dur-
ing pregnancy and instead used maternal hemoglobin at 1
month post-partum as an indirect measure. Hemoglobin
will reflect severe iron deficiency but cannot detect iron
deficiency without anemia. While research has indicated
that maternal hemoglobin during pregnancy can predict
decreases in birthweight, it has been extensively discussed
that a single biomarker of iron status is insufficient in
determining true iron status [8]. We were also unable to
take measures of ferritin, hemoglobin, mean corpuscular
volume, free erythrocyte protoporphyrin, and other mar-
kers of iron status during pregnancy due to the original
study design, since recruitment began at delivery. Without
more extensive measures of iron status we were unable to
assess iron deficiency without anemia or iron excess which
have both been linked with decreased birthweight in
numerous studies [12,13,38,42]. As a surrogate measure
for iron status we used hemoglobin measures at one
month post partum which was significantly associated
with a decrease in birthweight in our regression models
suggesting a role for iron metabolism in predicting birth-
weight. Previous studies have indicated that iron levels are
slightly elevated in heterozygous carriers of either HFE
C282Y or HFE H63 D genotypes [55]. In our study mater-
nal carriers of HFE H63 D variant genotypes did not have
significantly higher one month post-partum hemoglobin
measures (13.7 (1.6) μg/dL) when compared to wildtype
individuals (13.5 (1.5) μg/dL, P = 0.13), but we cannot
determine if their body iron stores were higher without
measures of ferritin or transferring saturation. Finally,
given the small sample size to test for interactions, these
results should be considered preliminary.
Conclusions
In summary, we found that infants (and mother-infant
pairs) who both carry the HFE H63 D variant have, on
average, lower birth weights. Additionally, infant HFE
H63 D variants may modify the negative effects of lead
biomarkers on birth weight by decreasing lead effects.
Conversely, mothers who carry an HFE H63 D variant
may enhance the negative effects of maternal bone lead
exposure on birthweight which may arise due to
increased oxidative damage during fetal development.
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